Details of the Drug Reposition

General Information of This Drug (ID: DM826SW)

Drug Name	PF-04236921 DM826SW

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Phase 2	[1]
Crohn disease	DIS2C5Q8	DD70	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01405196) Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)